Comprehensive Product Description Guide: Generic Brilinta (Ticagrelor)
What is Generic Brilinta used for?
Generic Brilinta (Ticagrelor) is an antiplatelet medication used to reduce the risk of heart attack, stroke, and cardiovascular death in patients with acute coronary syndrome (ACS) or a history of myocardial infarction. It works by preventing blood clots through inhibition of platelet aggregation.
Generic Brilinta
Ticagrelor

90 mg Tablets (twice daily dosing for ACS)

60 mg Tablets (once-daily maintenance after 12 months of ACS event)

Other Popular or Common Names:
Ticagrelor

Antiplatelet Ticagrelor

Brilinta Generic

Platelet Aggregation Inhibitor

P2Y12 Inhibitor
Therapeutic Class: Antiplatelet Agent

Pharmacological Class: P2Y12 Platelet Inhibitor

ATC Code: B01AC24

Prescription Only (Schedule S4 in Australia)
Ticagrelor
Ticagrelor selectively and reversibly inhibits the P2Y12 adenosine diphosphate (ADP) receptor on platelet surfaces, preventing activation and aggregation of platelets. Unlike clopidogrel, ticagrelor does not require metabolic activation, offering rapid onset and more consistent platelet inhibition.
Acute Coronary Syndrome (ACS)

History of Myocardial Infarction (to reduce recurrent CV events)

Prevention of thrombotic events after percutaneous coronary intervention (PCI)

Used in combination with low-dose aspirin (75–100 mg)
The PLATO trial (NEJM, 2009) demonstrated ticagrelor reduced the rate of death from vascular causes, myocardial infarction, or stroke compared to clopidogrel.

A sub-study confirmed ticagrelor's superiority even in high-risk patients with prior MI or stenting (Bonaca et al., Circulation, 2015).
Initial Dose for ACS:

180 mg orally (2 x 90 mg tablets) as a loading dose

Maintenance Dose (First 12 months):

90 mg orally twice daily

Always combined with low-dose aspirin (75–100 mg)

After 12 Months:

60 mg twice daily if long-term therapy is indicated
Administer with or without food

Do not exceed aspirin doses above 100 mg daily

Swallow whole; do not crush or split
Evaluate bleeding risk before initiating

Monitor renal and hepatic function in patients with impairment

Regularly assess adherence and dyspnea symptoms

Discontinue 5 days before surgery (if not urgent)
Dyspnea (shortness of breath)

Dizziness

Nausea

Headache

Bradycardia
Major bleeding (especially gastrointestinal, intracranial)

Ventricular pauses

Hyperuricemia

Severe hepatic impairment (contraindicated)
Bleeding risk: Avoid in patients with active bleeding or history of intracranial hemorrhage

Asthma or COPD: Dyspnea may worsen symptoms

Bradyarrhythmias: Monitor heart rhythm, especially in patients on beta-blockers

Not recommended for use in severe hepatic dysfunction

Use caution in renal impairment and elderly patients
Aspirin >100 mg/day: Reduces efficacy, increases bleeding

Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir): Increase ticagrelor levels

CYP3A4 inducers (e.g., rifampicin, phenytoin): Reduce efficacy

Statins (simvastatin, lovastatin >40 mg): Increased risk of side effects

Digoxin: Ticagrelor increases digoxin levels – monitor closely
Store below 25°C

Keep in original blister packaging

Protect from moisture and heat

Keep out of reach of children

Frequently Asked Questions (FAQs)
Q: What is Generic Brilinta used for?
A: Generic Brilinta (Ticagrelor) is used to prevent blood clots in people with acute coronary syndrome or a previous heart attack. It reduces the risk of death from cardiovascular causes, heart attack, or stroke.

Q: How is Generic Brilinta different from Clopidogrel?
A: Ticagrelor offers faster and more consistent platelet inhibition than clopidogrel, does not require activation by liver enzymes, and has shown better outcomes in large-scale studies like PLATO.

Q: Can I take Generic Brilinta with aspirin?
A: Yes, it should be taken with low-dose aspirin (75–100 mg/day). Higher doses reduce its effectiveness and increase bleeding risk.

Q: What should I do if I miss a dose?
A: Skip the missed dose and take your next dose at the regular time. Do not double up.

Q: Is it safe during pregnancy or breastfeeding?
A: Ticagrelor is not recommended during pregnancy or breastfeeding due to potential bleeding risk to the fetus or infant.

Q: What should I watch for while taking Ticagrelor?
A: Signs of bleeding (bruising, nosebleeds, blood in stool/urine), shortness of breath, or irregular heartbeat should be reported immediately.
Buy Generic Brilinta online Australia

Ticagrelor 90 mg tablets for heart patients

Antiplatelet medication for heart attack prevention

Brilinta vs Clopidogrel comparison

Platelet inhibitor therapy for ACS

Ticagrelor heart medication uses and side effects

Brilinta generic cost and dosage

Dual antiplatelet therapy with aspirin and ticagrelor

Prescription antiplatelet drug online

Ticagrelor PLATO trial data

Ticagrelor antiplatelet tablets

Generic Brilinta 90 mg

ACS treatment post-stent

Prevent heart attack and stroke

Dual antiplatelet therapy

Reversible P2Y12 inhibitor

PLATO trial supported therapy

Post-MI clot prevention

Prescription blood thinner

Cardiovascular protection drug